U.S., April 29 -- ClinicalTrials.gov registry received information related to the study (NCT07553988) titled 'A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer' on April 21.
Brief Summary: The primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of different doses of RS-113 versus abiraterone, as well as to investigate pharmacokinetics profile and to perform a pilot evaluation of pharmacokinetics parameters of RS-113 in patients with metastatic castration-resistant prost...